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ABSTRACT 
Objective: Replication of associations in genome-wide association studies (GWAS) 
is desirable to ensure that such signals are potentially clinically meaningful. This 
study aimed to replicate associations of selected single-nucleotide polymorphisms 
(SNPs) with hypothyroidism and serum thyroid stimulating hormone (TSH) using 
electronic medical records (EMRs). 
Methods: A cross-sectional study was done among patients of European Caucasian 
ethnicity from the Genetics of Diabetes Audit and Research Tayside (GoDARTS) 
recruited in Tayside (Scotland, UK). EMRs (biochemistry, prescribing, hospital 
admissions and demographics) were used to ascertain patients with hypothyroidism 
and their controls as well as average serum TSH concentration, and linked to genetic 
biobank data. Genetic tests of association were performed by means of logistic and 
linear regression models. 
Results: We analysed 1,703 cases of hypothyroidism and 9,457 controls. All four 
SNPs located on chromosome 9 at FOXE1 were associated with hypothyroidism with 
similar effect estimates (OR= 0.75- 0.76, P<5e-08). Also loci on chromosomes 1 
(PTPN22), 6 (HLA-E/HLA-C) and 12 (SH2B3) were replicated. For serum TSH we 
confirmed twelve SNPs previously reported at PDE8B, CAPZB, PDE10A, 
LOC105371356, NR3C2, VEGFA, IGFBP5, INSR, PRDM11, NFIA, ITPK1, and 
ABO. Overall, these SNPs accounted for 6.8% of the serum TSH variation (P<1e-04). 
Conclusions: EMRs linked to genomic data in large populations allows validation of 
GWAS discoveries without additional genotyping costs. Our replication confirmed at 
genome-wide significance the association of loci at FOXE1 with hypothyroidism, and 
PDE8B, CAPZB and PDE10A with serum TSH. Twelve SNPs seemed to explain 
nearly 7% of the serum TSH variation. 
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INTRODUCTION 
Hypothyroidism is a common thyroid disorder affecting about 3-5% of the general 
population (1, 2). Treatment includes thyroid hormone replacement therapy, and 
levothyroxine (thyroxine sodium) is the treatment of choice for maintenance. Patients 
usually respond well to treatment, and the dose is usually monitored in response to a 
combination of patients’ symptoms and thyroid stimulating hormone (TSH) serum 
levels (3).  
 
Genome-wide association studies (GWAS) have found association signals with 
hypothyroidism and serum TSH levels (4-6). However, replication studies are scarce 
and desirable to help ensure that a genotype-phenotype association observed in a 
GWAS represents a credible association. Replication of an association requires 
genotyping the initially discovered genetic variant in a completely independent 
sample of sufficient size (7). 
 
Recently, electronic medical records (EMR)-derived phenotypes are being linked to 
genetic biobanks to allow research on the genetic basis of a wide range of traits highly 
cost effectively (8). Therefore such EMR-linked biobanks might be appropriate to 
investigate the role that genetics play in thyroid related disorders. 
 
Using the Genetics of Diabetes and Audit Research Tayside Study (GoDARTS) 
dataset, we aimed to replicate the association of selected GWAS-identified loci with 
the diagnosis of hypothyroidism and with average serum TSH levels in a Scottish 
population. 
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METHODS 
A cross-sectional study was done among patients from the GoDARTS population 
recruited in Tayside, Scotland (UK). All subjects in this population are of white 
ethnicity and have previously been described elsewhere (9). Each subject has a unique 
patient identification number (Community Health Index-CHI) which facilitates 
anonymous data linkage across all available EMRs by the Health Informatics Centre 
of the University of Dundee (http://www.dundee.ac.uk/hic). Records on redeemed 
drug prescriptions, demography and biochemistry, and several databases were linked 
to genetic data. Databases included the Scottish Care Information-Diabetes 
Collaboration- SCIDC, the Scottish Morbidity Records- SMR (hospital admissions 
and cancer registry), Radioiodine, and the Office of Population Censuses and Surveys 
Classification of Surgical Operations version 4- OPCS4. 
 
Phenotype definition criteria 
All patients with at least one serum TSH recording between 1994 and 2014 were 
considered for inclusion in this study. A phenotype of all-cause hypothyroidism (i.e. 
cases) was defined as having been issued at least two prescriptions for thyroid 
replacement therapy (British National Formulary codes-BNF 6.2.1) during the study 
period. Controls never received a prescription for thyroid replacement therapy or 
received just one. 
Patients with history of thyroid cancer or probable hyperthyroidism were excluded. 
Probable hyperthyroidism was considered as having at least one OPCS4 code of 
treatment with thyroid surgery (OPCS4: B08, B09, B12), radioactive iodine and/or a 
prescription of anti-thyroid drug use (BNF 6.2.2). At least one International 
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Classification of Diseases (ICD) 9th-10th edition code (ICD9: 193; ICD10: C73, D093, 
D440) was required for thyroid cancer. 
The TSH (average) was taken as the median of serum TSH measures recorded 
throughout the study period for each patient. Euthyroid subjects had a normal average 
TSH serum level (defined as 0.4 to 4.0 mIU/L) and never received thyroid 
medication. 
 
Genetic data  
Genotype data was available from the following platforms: the Human Exome -12 
VI_A_chip, the Metabohip (10), Illumina HumanOmni Express -12VI platform 
(Illumina, San Diego), Affymetrix 6.0 platform (Affymetrix, Santa Clara) and the 
Illumina Infinium custom GWAS chip (Illumina, San Diego). Imputation was 
performed against 1000G Phase I V3 reference panel using Impute2 (11) and using 
the haplotype reference consortium (12); calls made with imputation quality below 
90% were discarded. All SNPs were in Hardy-Weinberg equilibrium (P<10e-04). 
 
Selection of genetic loci to be tested 
Association signals reported by latest powered GWAS on hypothyroidism (4, 5) and 
serum TSH levels (6). 
 
Statistical analysis 
ANOVA and chi-square tests were used to compare means and frequencies among 
groups of patients respectively, and nonparametric tests were used where 
appropriate(13). Single-locus tests of association with hypothyroidism (coded as 
binary) were performed on cases and controls by logistic regression under the 
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assumption of an additive genetic model. Odds ratios (OR) from logistic models were 
adjusted for age at first TSH recording and gender. Linear regression models were 
used on euthyroid subjects to test the association with average serum TSH levels and 
to estimate the proportion of variation of TSH explained by the SNPs. Fixed effects 
meta-analyses were performed to assess the consistency of effects of this study with 
the previously reported ones, and heterogeneity was quantified using the I-squared 
measure(14). Statistical analyses were conducted using STATA/SE version 13.1 
software (StataCorp, TX, USA) and the statistical significance level set at P<5e-0.2.  
The significance threshold was further adjusted with Bonferroni correction for the 
number of independent SNPs simultaneously tested. 
 
Ethical approval 
All analyses were performed on anonymised datasets. The study was approved by the 
Tayside Medical Ethics Committee, and informed consent had been obtained for all 
participants. 
 
RESULTS  
We identified 16,464 individuals as being eligible for the study, of which 2,484 had 
hypothyroidism (cases) and 13,980 did not (controls), and up to 11,160 (i.e. 1,703 
cases and 9,457 controls) had available genomic data in the GoDARTS biobank. 
Compared to controls, cases were mostly women (73 vs 43.4%, P<1e-03), had a 
higher average serum TSH level (2.2 vs 1.7 mIU/L, P<1e-03), but there was no 
difference in age (57 years). 
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Table 1 shows the adjusted ORs for SNPs associated with hypothyroidism that were 
identified through published GWAS. All four SNPs located on chromosome 9 at 
FOXE1 (rs965513, rs10759944, rs925489 and rs7850258) were associated with 
hypothyroidism at P<5e-08 with similar effect estimates (OR= 0.75- 0.76). These four 
SNPs were in strong linkage disequilibrium (r2>0.99). An additional fifth 
polymorphism near FOXE1 (rs1877432) did not reach statistical significance. We did 
not find an association for several SNPs located on the same chromosome at DFNB31 
(rs1535971, rs4979402, rs4979397 and rs1408528). In addition to the associations 
found on chromosome 9 at FOXE1, we found significant associations on chromosome 
1 at PTPN22 (rs6679677 and rs2476601; P<1.9e-03). 
 
Within the control group there were 9,125 euthyroid patients (i.e. 96% of the controls) 
aged 57.4 years, 43.4% were women, and had an average serum TSH level of 1.72 
mIU/L. For serum TSH concentration  in this subgroup (table 2), we confirmed twelve 
out of twenty statistically significant SNPs previously reported  at PDE8B, CAPZB, 
PDE10A, LOC105371356, NR3C2, VEGFA, IGFBP5, INSR, PRDM11, NFIA, ITPK1, 
and ABO; the coded allele was associated with increased TSH in five of them 
(PDE10A, LOC105371356, NR3C2, IGFBP5, and ABO). Each copy of the coded 
allele of rs6885099 at PDE8B (Phosphodiesterase type 8B) was associated with a 
decrease of 0.13 mIU/L serum TSH. This SNP accounted for 1.46% of serum TSH 
variation, followed by signals in the capping protein- actin filament muscle Z-line β 
(CAPZB- rs10799824) and the phosphodiesterase type 10A (PDE10A- rs753760) that 
contributed to 0.74% and 0.71% of variation respectively. Further adjustment of 
regression models for age and gender did not change the size and direction of the 
effect estimates. When combined, the twelve significantly associated SNPs accounted 
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for 6.47% (n=5,241, P<1e-04) of the TSH variation, that increased to 6.83% after also 
including age and gender as predictors in the linear model, thus leaving 0.36% (i.e. 
6.83- 6.47%) of the variation to age and gender. Male gender was associated with a 
lower serum TSH (β= -0.052, P=1.2e-02), and each additional year of life conferred 
an increase of 0.003 mIU/L serum TSH (P=1.2e-04). 
 
The consistency of SNPs effects of this study with the previously reported studies was 
shown in figures 1 and 2. Heterogeneity was quantified using the I-squared measure, 
and a value of 0% (i.e. no observed heterogeneity) was obtained in almost all meta-
analyses. Although no significant heterogeneity was detected, a value close to 50% 
was found in two of the meta-analyses (figure 1, PTPN22-rs2476601 on 
hypothyroidism; figure 2, ABO-rs657152 on average serum TSH). 
 
DISCUSSION 
This was a record-linkage study using electronic databases to validate novel genetic 
loci discovered in GWA studies with hypothyroidism and serum TSH levels in a 
Scottish Caucasian population from the GoDARTS database. 
 
Phenotype definition is critical in this kind of studies. Patients that received one 
thyroid replacement therapy prescription were not excluded from the control group 
because did not differ from the rest of controls. There were 252 of these patients in the 
control group that had normal TSH values (1.730 mIU/L) similar to controls that 
never received replacement therapy (1.735 mIU/L). Besides, their inclusion could not 
result in underestimation of the genetic association effects because they represent less 
than 3% of the controls. Thus, we found no reason to exclude them. 
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Four SNPs in linkage disequilibrium at FOXE1 (thyroid transcription factor 2) were 
replicated in this study with hypothyroidism, the strongest being rs965513. Loci in 
HLA, SH2B3, PTPN22, CTLA4, PDE8B and VAV3 were also replicated. The 
association between FOXE1 and hypothyroidism was first reported by Denny et al. in 
a GWAS of 1,317 cases and 5,053 controls identified from EMRs, and subsequently 
by Eriksson et al. in the largest GWAS to date of hypothyroidism of 3,736 cases and 
35,546 controls of European ancestry (4, 5). Some of these genes have known 
immune functions (HLA, SH2B3, PTPN22, CTLA4, and VAV3) and others in thyroid 
function (FOXE1, CAPZB and PDE8B). Our associations consistently replicate the 
effect size and direction of these loci, despite slightly different phenotypes reported by 
others. Denny et al. searched EMRs for the presence of a thyroid replacement 
medication for at least three months and at least one ICD code for hypothyroidism.  
Eriksson et al. used self-administered web-based questionnaires for phenotype 
identification; cases were those that answered “yes” to hypothyroidism or to elevated 
TSH levels or to taking medication for hypothyroidism. We did not query ICD codes 
for phenotype definition as this would have missed the majority of cases with 
hypothyroidism that did not have a hospital admission. 
 
Porcu et al. carried out an analysis of 26,420 subjects pooled from 18 cohorts to 
identify novel loci related to serum TSH (6). Prior to GWAS they had excluded those 
with thyroid pathologies, thyroid surgery and/or thyroid medication, as well as those 
with levels outside the normal TSH range. Overall, their 20 reported loci explained 
5.6% of TSH variation in euthyroid subjects. Our study confirmed twelve of these 
reported associations, which combined accounted for a larger serum TSH variation 
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(6.5%). As expected, male gender was associated with a lower serum TSH (15). We 
acknowledge that the higher variance observed from fewer variants could be due to 
our smaller sample size (as compared to Porcu et al.). However, the allele frequency 
from our study (see table 2) did not differ from that reported by Porcu et al (6). It is 
plausible that since the causal variants have still not been confirmed through 
functional studies, that the Scottish Caucasian population shows a different LD 
structure between these common SNPs and the causal variants. However, given the 
lack of differences in TSH levels between the compared populations (i.e. GoDARTS 
of 1.73mIU/L and Porcu et al. of 1.78 mIU/L), this would be unlikely.  
 
The meta-analyses of the association test results between significant SNPs and 
hypothyroidism or serum TSH observed across studies indicate that variability 
between estimated effects from this current study and the previously reported ones 
can be explained by chance only. 
 
In summary, EMR-linked genomic data allowed replication of discovered genes 
associated with several traits without additional genotyping costs. Replication 
confirmed at genome-wide significance the association of loci in FOXE1 with 
hypothyroidism, and PDE8B, CAPZB and PDE10A with serum TSH. The GoDARTS 
database seems to be appropriate to research on genetic associations of thyroid traits, 
and the identified set of SNPs explains nearly 7% of variation in serum TSH 
concentration. 
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FIGURE LEGENDS 
Figure 1 Forest plot representing meta-analysis of the association test results between 
significant SNPs at Bonferroni threshold and hypothyroidism observed across 
GoDARTS, Denny et al.[4], and Eriksson et al.[5] studies. Results from logistic 
regression models are presented; odds ratios are per copy of the coded allele. 
 
Figure 2 Forest plot representing meta-analysis of the association test results between 
significant SNPs at Bonferroni threshold and average serum TSH concentration 
observed across GoDARTS and Porcu et al.[6] studies. Results from linear regression 
models are presented; coefficients are per copy of the coded allele.  
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Figure 2 
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TABLE 1.  SNPs associated with hypothyroidism. 
 
        GoDARTS         PRIOR ASSOCIATION 
       Coded 
Gene  SNP  CHR  Position allele MAF Cases† Controls† ORφ (95%CI)  P   OR (95%CI)  P 
 
FOXE1  rs965513   9 100556109 A 0.34 1,670 9,250  0.76 (0.70- 0.82)  7.6e-11* 0.74 (0.67- 0.82)1  4.1e-09 
FOXE1  rs10759944   9 100556972 A 0.34 1,669 9,260  0.76 (0.70- 0.82)  1.0e-10* 0.75 (0.68- 0.83)1  8.1e-09 
FOXE1  rs925489   9 100546600 C 0.34 1,212 5,937  0.75 (0.68- 0.83)  3.8e-08* 0.74 (0.67- 0.82)1  4.6e-09 
                 0.78 (0.74- 0.82)2  2.4e-19 
FOXE1   rs7850258   9 100549013 A  0.34 1,212 5,937  0.76 (0.68- 0.83)  4.7e-08* 0.74 (0.67- 0.82)1  3.9e-09 
HLA-E/HLA-C  rs2517532   6   31018407 A 0.42 1,703 9,457  0.85 (0.79- 0.92)  7.5e-05* 0.86 (0.82- 0.91)2  1.3e-08 
SH2B3  rs3184504 12 111884608 C 0.49 1,410 7,573  0.84 (0.78- 0.92)  9.4e-05* 0.84 (0.79- 0.88)2  2.6e-12 
PTPN22  rs6679677   1 114303808 A 0.09 1,695 9,403  1.25 (1.10- 1.41)  3.0e-04* 1.36 (1.26- 1.48)2  2.8e-13 
PTPN22  rs2476601   1 114377568 A 0.09 1,662 9,281  1.22 (1.07- 1.38)  1.9e-03* 1.36 (1.25- 1.47)2  3.9e-13 
CTLA4  rs231779   2 204734487 T 0.40 1,208 5,908  1.15 (1.05- 1.26)  2.2e-03  1.12 (1.07- 1.19)2  7.0e-06 
PDE8B  rs4704397   5   76518442 A 0.37 1,212 5,937  1.14 (1.04- 1.25)  5.0e-03  1.17 (1.10- 1.26)2  2.1e-06 
VAV3  rs4915077   1 108366016 C 0.08 1,208 5,908  1.22 (1.05- 1.43)  9.9e-03  1.30 (1.20- 1.42)2  7.5e-10 
near FOXE1 rs1877432   9 100543880 A 0.39 1,212 5,937  1.08 (0.98- 1.18)  8.4e-02  1.25 (1.14- 1.37)1  1.9e-06 
PVT1  rs4733792   8 128840276 T 0.41 1,212 5,937  0.95 (0.87- 1.05)  3.8e-01  1.18 (1.08- 1.30)1  2.3e-04 
PVT1  rs4733789   8 128834403 C 0.41 1,212 5,937  0.95 (0.87- 1.05)  3.6e-01  1.17 (1.07- 1.28)1  5.5e-04 
CAPZB   rs1472565   1   19755030 C 0.49 1,198 5,876  1.03 (0.94- 1.12)  5.2e-01  1.11 (1.05- 1.16)2  6.3e-05 
DFNB31 rs1535971   9 117229400 T 0.06 1,200 5,894  1.03 (0.92- 1.14)  5.5e-01  1.27 (1.15- 1.40)1  3.6e-06 
DFNB31 rs4979402   9 117222675 G 0.24 1,202 5,904  1.02 (0.91- 1.13)  7.1e-01  1.29 (1.16- 1.42)1  1.2e-06 
closest to KIT  rs17827152   4   55478686 A 0.23 1,171 5,742  0.97 (0.87- 1.09)  7.1e-01  1.28 (1.15- 1.42)1  3.2e-06 
HLA-DRB1 rs2516049   6   32570400 C 0.32 1,018 5,099  1.01 (0.91- 1.12)  7.9e-01      1.15 (1.09- 1.21)2  6.0e-07 
DFNB31 rs4979397   9 117219888 T 0.24 1,203 5,891  1.01 (0.91- 1.12)  8.1e-01  1.28 (1.16- 1.42)1  1.9e-06 
DFNB31 rs1408528   9 117220773 C 0.24 1,203 5,891  1.01 (0.91- 1.12)  8.1e-01  1.28 (1.16- 1.42)1  2.0e-06 
SHQ1  rs17043990   3   72880470 C 0.01 1,212 5,937  1.12 (0.31- 4.03)  8.6e-01  3.71 (2.08- 6.60)1  8.3e-06 
CCBE1  rs1791303 18   57455226 T 0.40 1,167 5,690  1.00 (0.91- 1.10)  9.6e-01  0.83 (0.75- 0.91)1  6.7e-04 
CCBE1  rs4940904 18   57455061 T 0.40 1,212 5,937  1.00 (0.91- 1.09)  9.9e-01  0.83 (0.76- 0.91)1  1.1e-04 
TBL1X   rs17280788 X --  T -- (Not available)   --   --  1.14 (1.02- 1.28)1  1.9e-02 
CHR= chromosome. MAF= Minor allele frequency. SNP= single-nucleotide polymorphism. (φ) Logistic regression models adjusted for age and gender. (†) Number of subjects used for the 
association test. (*) SNPs reaching the Bonferroni significance threshold at α=0.05/24= 2.1e-03. 
(1) Denny JC, Crawford DC, Ritchie MD et al. Am J Hum Genet 2011; 89(4): 529- 42. 
(2) Eriksson N, Tung JY, Kiefer A, et al. PLoS One 2012; 7(4): e34442.  
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TABLE 2. SNPs associated with average TSH levels in euthyroid subjects. 
 
         GoDARTS       PRIOR ASSOCIATION  
       Coded 
Gene  SNP  CHR  Position allele  Freq. N† β (SE)φ  P  % Var.  β (SE) 1  P 
 
PDE8B   rs6885099   5   76530349 A  0.61 8,896 -0.131 (0.011) 2.3e-30* 1.46  -0.141 (0.009) 1.9e-56 
CAPZB   rs10799824   1   19841174 A  0.15 5,710 -0.125 (0.019) 6.6e-11* 0.74  -0.113 (0.012) 3.6e-21 
PDE10A rs753760   6 166046483 C  0.69 5,637  0.098 (0.015) 2.1e-10* 0.71   0.100 (0.010) 1.2e-24 
LOC105371356 rs3813582 16   79749353 T  0.69 5,711  0.080 (0.015) 1.5e-07* 0.48   0.082 (0.010) 8.4e-18 
NR3C2  rs10032216   4 149669506 T  0.79 5,714  0.088 (0.016) 2.1e-07* 0.47   0.087 (0.011) 9.2e-16 
VEGFA   rs9472138   6   43811762 T  0.30 9,125 -0.062 (0.012) 2.2e-07* 0.29  -0.079 (0.010) 6.7e-16 
IGFBP5  rs13015993   2 217625523 A  0.73 5,715  0.074 (0.015) 2.0e-06* 0.39   0.078 (0.010) 3.2e-15 
INSR   rs4804416 19     7223848 T  0.57 5,715 -0.066 (0.014) 3.5e-06* 0.38  -0.057 (0.009) 3.1e-10 
PRDM11 rs17723470 11   45227567 T  0.30 5,467 -0.065 (0.015) 2.7e-05* 0.32  -0.065 (0.010) 8.8e-11 
NFIA   rs334699   1   61620496 A  0.05 5,704 -0.134 (0.032) 3.2e-05* 0.30  -0.141 (0.021) 5.4e-12 
ITPK1  rs11624776 14   93595591 A  0.68 5,597 -0.052 (0.015) 5.6e-04* 0.21  -0.064 (0.011) 1.7e-09 
ABO   rs657152       9 136139265 A  0.31 9,125  0.038 (0.011) 1.3e-03* 0.13   0.058 (0.009) 4.1e-10 
NRG1  rs7825175   8   32416274 A  0.20 5,715 -0.052 (0.017) 2.9e-03  0.16  -0.066 (0.011) 2.9e-09 
MIR1179 rs17776563 15   89119104 A  0.32 5,639 -0.037 (0.015) 1.3e-02  0.11  -0.060 (0.010) 2.8e-10 
VEGFA   rs11755845   6   43904780 T  0.24 5,715 -0.039 (0.016) 1.7e-02  0.10  -0.065 (0.010) 1.6e-10 
GLIS3  rs1571583   9     4267209 A  0.21 8,880  0.023 (0.013) 9.2e-02  0.03   0.057 (0.010) 2.5e-08 
SOX9  rs9915657 17   70127536 T  0.51 5,528 -0.016 (0.011) 2.7e-01  0.02  -0.064 (0.009) 7.5e-13 
SASH1  rs9497965   6 148521292 T  0.40 5,243  0.011 (0.010) 4.5e-01  0.01   0.051 (0.009) 2.2e-08 
FGF7  rs10519227 15   49746364 A  0.24 5,619 -0.008 (0.012) 5.7e-01  0.01  -0.072 (0.011) 1.0e-11 
MBIP   rs1537424 14   36574018 T  0.59 5,715 -0.005 (0.014) 7.4e-01  0.01  -0.052 (0.009) 1.1e-08 
CHR= chromosome. Freq= Coded allele frequency. SE= standard error. SNP= single-nucleotide polymorphism. TSH= thyroid stimulating hormone. %Var= Percentage of variation within the 
phenotype explained by the polymorphism. (φ) Univariate linear regression models; β=effect size (mIU/L). (†) Number of subjects used for the association test. (*) SNPs reaching the 
Bonferroni significance threshold at α=0.05/20= 2.5e-03 
(1) Porcu E, Medici M, Pistis G, et al. PLoS Genetics 2013; 9(2): e1003266. 
 
 
